An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesResearch in context

Summary: Background: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant chole...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Beryl B. Cummings, Page R. Bouchard, Mark N. Milton, Peter F. Moesta, Vyas Ramanan, John W. Trauger, Eleftheria Maratos-Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Keith DiPetrillo, Daniel LaSala, Meihui Pan, Meghan M. Flaherty, Francois Huet, Sukhdeep K. Sahambi, Jijun Dong, Deborah Knee, Regis Cebe, Thomas Huber, Joshua Lehrer-Graiwer, Rebecca A. Juliano, Ethan J. Weiss
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2025-07-01
Serie:	EBioMedicine
Ämnen:	MAR001 ANGPTL4 Triglyceride Remnant cholesterol Non-human primates Safety
Länkar:	http://www.sciencedirect.com/science/article/pii/S2352396425001926
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!